drugset / Trial / NCT01105546
rFVIIa Prophylaxis in Children With Hemophilia A and Inhibitors
RandomizedParallel-groupOpen-labelTreatment
Summary
The study evaluates the efficacy and safety of a prophylactic treatment with recombinant activated FVII in reducing the frequency of joint bleeds and the development of joint damage in children with hemophilia A who develop high-titer inhibitors.
Timeline
- Start
- 2010-12
- Primary completion
- 2014-02
- Completion
- 2014-04
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Comparator | eptacog alfa (activated) | Protein / enzyme biologic | 90 ug/kg | Intravenous |
| Comparator | eptacog alfa (activated) | Protein / enzyme biologic | 270 ug/kg | Intravenous |